Suzigan Sueli, López-Beltrán Antonio, Montironi Rodolfo, Drut Ricardo, Romero Ana, Hayashi Tomayoshi, Gentili Ana L C, Fonseca Paulo S P, deTorres Ines, Billis Athanase, Japp Lucia C, Bollito Enrico, Algaba Ferran, Requena-Tapias Maria J
Laborclin Laboratory, São José do Rio Prêto, Brazil.
Am J Clin Pathol. 2006 Feb;125(2):217-22. doi: 10.1309/AH6F-C77P-YR2V-6YAY.
The 2004 World Health Organization (WHO) classification of kidney tumors recognizes multilocular cystic renal cell carcinoma (MCRCC) as a rare variant of clear cell renal cell carcinoma with a good prognosis. Available information on its clinical significance is limited. The study cohort included 45 MCRCC cases classified according to 2004 WHO criteria obtained through a multi-institutional international search. Most patients had unilateral MCRCC with no side predominance that was found incidentally; 62% were men, but women had tumors at an earlier age (P = .385). MCRCC occurred slightly more often in men than in women (1.7:1). At diagnosis, 82% of patients had stage T1 and 16%, stage T2; 1 patient had stage T3. The Fuhrman grade was 1 (62%) or 2 (38%), with smaller tumors (<or=4 cm) most likely Fuhrman grade 1 (P = .911). All 45 patients were alive with no evidence of disease at mean follow-up of 66.1 months, confirming an extremely good prognosis after surgery and a 5-year disease-specific survival rate of 100%. To rename this tumor as multilocular cystic renal cell neoplasm of low malignant potential might help urologists approach the patients conservatively.
2004年世界卫生组织(WHO)的肾肿瘤分类将多房囊性肾细胞癌(MCRCC)认定为透明细胞肾细胞癌的一种罕见变体,预后良好。关于其临床意义的现有信息有限。该研究队列包括通过多机构国际检索获得的45例根据2004年WHO标准分类的MCRCC病例。大多数患者为单侧MCRCC,无明显的左右侧优势,多为偶然发现;62%为男性,但女性发病年龄较早(P = 0.385)。MCRCC在男性中的发生率略高于女性(1.7:1)。诊断时,82%的患者为T1期,16%为T2期;1例患者为T3期。Fuhrman分级为1级(62%)或2级(38%),较小的肿瘤(≤4 cm)最可能为Fuhrman 1级(P = 0.911)。45例患者均存活,平均随访66.1个月时无疾病证据,证实手术后预后极佳,5年疾病特异性生存率为100%。将该肿瘤重新命名为低恶性潜能多房囊性肾细胞瘤可能有助于泌尿外科医生对患者采取保守治疗方法。